CAPTEM has a relatively minimal role in the management of neuroendocrine carcinoma (NEC) and is almost exclusively used in later lines of therapy after first-line platinum/etoposide. In general, second-line therapy of NEC is ineffective and a retrospective study of 64 patients receiving various regi...